Emmyon is a biotechnology company focused on understanding and combating muscle atrophy, particularly as it relates to aging, illness, and injury. The company employs a research methodology that begins with human skeletal muscle biopsies to analyze mRNA expression signatures associated with muscle atrophy. By identifying small molecules that exhibit opposing mRNA signatures, Emmyon aims to discover potential inhibitors of muscle atrophy. This process includes in vivo studies in mouse models to evaluate the safety and efficacy of these small molecules, with promising candidates like ursolic acid and tomatidine being advanced for commercial applications in humans and animals.

In addition to its work on human muscle health, Emmyon is also developing innovative feed additives derived from natural compounds found in fruits and vegetables. These additives are designed to promote muscle growth in livestock, offering a safer alternative to traditional beta agonists and antibiotics, which face regulatory challenges. By leveraging their understanding of muscle biology, Emmyon aims to create effective solutions for enhancing muscle mass and strength in both production animals and pets, thereby improving overall health and quality of life.

United States

Emmyon - Discovery and development of small molecules that improve muscle mass, strength and metabolism 
Commercialization of small molecules through licensing agreements and partnerships with consumer-facing companies 
Funded by private investors and the National Institutes of Health

Emmyon

Company Details